While oncologics remain the mainstay of US FDA’s flagship regulatory incentive program, the breakthrough therapy designation (BTD), recent awards illustrate how the program is encouraging development for unmet needs within big markets like respiratory disease and dermatology.
Respiratory disease, one of AstraZeneca PLC’s primary areas of focus for R&D, has now earned the company a breakthrough...








